Utah Medical Products, Inc. (NASDAQ:UTMD - Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $57.02 and traded as low as $55.21. Utah Medical Products shares last traded at $55.55, with a volume of 14,575 shares traded.
Utah Medical Products Stock Performance
The firm has a market capitalization of $189.67 million, a P/E ratio of 15.44 and a beta of 0.28. The stock has a 50-day moving average of $55.85 and a 200 day moving average of $56.97.
Utah Medical Products (NASDAQ:UTMD - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical instruments supplier reported $0.94 EPS for the quarter. Utah Medical Products had a net margin of 33.00% and a return on equity of 10.74%. The business had revenue of $9.95 million for the quarter.
Utah Medical Products Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 3rd. Shareholders of record on Monday, June 16th were paid a $0.305 dividend. The ex-dividend date of this dividend was Monday, June 16th. This represents a $1.22 dividend on an annualized basis and a yield of 2.09%. Utah Medical Products's payout ratio is presently 32.28%.
Hedge Funds Weigh In On Utah Medical Products
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its position in shares of Utah Medical Products by 12.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 13,119 shares of the medical instruments supplier's stock worth $735,000 after purchasing an additional 1,421 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Utah Medical Products by 134,400.0% during the first quarter. GAMMA Investing LLC now owns 4,035 shares of the medical instruments supplier's stock worth $226,000 after purchasing an additional 4,032 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Utah Medical Products by 14.8% during the fourth quarter. JPMorgan Chase & Co. now owns 79,703 shares of the medical instruments supplier's stock worth $4,899,000 after purchasing an additional 10,292 shares in the last quarter. Millennium Management LLC boosted its position in shares of Utah Medical Products by 27.8% during the fourth quarter. Millennium Management LLC now owns 32,087 shares of the medical instruments supplier's stock worth $1,972,000 after purchasing an additional 6,975 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Utah Medical Products by 5.1% during the fourth quarter. Northern Trust Corp now owns 36,832 shares of the medical instruments supplier's stock worth $2,264,000 after purchasing an additional 1,773 shares in the last quarter. 69.60% of the stock is owned by institutional investors.
About Utah Medical Products
(
Get Free Report)
Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.
Recommended Stories
Before you consider Utah Medical Products, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Utah Medical Products wasn't on the list.
While Utah Medical Products currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access